Doc's Opinion. Recently, non-HDL cholesterol non-HDL-C has become a commonly used marker for a blood lipid pattern associated with increased risk of heart disease. Atherosclerosis is the most common underlying cause of cardiovascular disease. It is due by a complex interplay between lipoproteins, white blood cells macrophages , the immune system and the natural elements of the arterial wall. Lipoproteins that are directly involved in atherosclerosis are termed atherogenic.
|Published (Last):||22 April 2005|
|PDF File Size:||10.3 Mb|
|ePub File Size:||6.97 Mb|
|Price:||Free* [*Free Regsitration Required]|
Each patient received 10 mg of pravastatin daily for 3 months. Plasma total cholesterol and low-density lipoprotein cholesterol levels decreased significantly during treatment and high-density lipoprotein cholesterol levels increased significantly. Above-normal plasma levels of thrombin-antithrombin III complex, fibrinopeptide A, FDP-D-dimer, plasminogen activator inhibitor-I, and thrombomodulin were found in the patients before treatment; each of these was reduced significantly during treatment.
The findings suggest the presence of a hypercoagulable state in hypercholesterolemia and that pravastatin might prevent the hypercoagulable state by reducing hypercholesterolemia.
Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection.
Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again. Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items.
Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel. Cite Favorites. Similar articles Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Dangas G, et al. Thromb Haemost. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B, et al. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Davis SR, et al. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia.
Arch Intern Med. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH, et al. Clin Ther. Show more similar articles See all similar articles. Cited by 9 articles Clinical effects of antiplatelet drugs and statins on D-dimer levels. Schol-Gelok S, et al. Eur J Clin Invest. Epub May Clinical Trial. Edible bird's nest attenuates procoagulation effects of high-fat diet in rats. Yida Z, et al. Drug Des Devel Ther. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
Bolaman Z, et al. J Natl Med Assoc. Urbauer E, Joukhadar C. Urbauer E, et al. Wien Med Wochenschr. PMID: Review. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins. Wiesbauer F, et al. Br J Pharmacol. Show more "Cited by" articles See all "Cited by" articles.
Publication types Research Support, Non-U. Gov't Actions. MeSH terms Adult Actions. Aged Actions. Blood Coagulation Tests Actions.
Female Actions. Humans Actions. Male Actions. Middle Aged Actions. Substances Biomarkers Actions. Cholesterol, HDL Actions. Cholesterol, LDL Actions. Fibrin Fibrinogen Degradation Products Actions. Antithrombin III Actions. Cholesterol Actions. Pravastatin Actions. Copy Download.
The Triglyceride/HDL Cholesterol Ratio
Hypercoagulable State in Patients With Hypercholesterolemia: Effects of Pravastatin
Each patient received 10 mg of pravastatin daily for 3 months. Plasma total cholesterol and low-density lipoprotein cholesterol levels decreased significantly during treatment and high-density lipoprotein cholesterol levels increased significantly. Above-normal plasma levels of thrombin-antithrombin III complex, fibrinopeptide A, FDP-D-dimer, plasminogen activator inhibitor-I, and thrombomodulin were found in the patients before treatment; each of these was reduced significantly during treatment. The findings suggest the presence of a hypercoagulable state in hypercholesterolemia and that pravastatin might prevent the hypercoagulable state by reducing hypercholesterolemia.
Non-HDL Cholesterol (Non-HDL-C)
Doc's Opinion. For many different reasons, lowering LDL-C has become a primary goal in cardiovascular prevention. There is substantial evidence available suggesting a relationship between LDL-C and the risk of coronary heart disease. Medical professionals usually recommend lifestyle measures that lower LDL-C and statins cholesterol-lowering drugs are used by millions of people worldwide for the sole purpose of lowering LDL-C numbers.